Generation Bio Competitors

Generation Bio (NASDAQ:GBIO) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Generation Bio and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Generation Bio.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Ionis Pharmaceuticals has a consensus target price of $57.9091, indicating a potential upside of 36.71%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Ionis Pharmaceuticals.

Summary

Ionis Pharmaceuticals beats Generation Bio on 6 of the 8 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Sarepta Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Generation Bio and Sarepta Therapeutics' revenue, earnings per share and valuation.

Generation Bio has higher earnings, but lower revenue than Sarepta Therapeutics.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Sarepta Therapeutics, as provided by MarketBeat.com.

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Sarepta Therapeutics has a consensus target price of $150.4762, indicating a potential upside of 113.32%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Generation Bio.

Summary

Sarepta Therapeutics beats Generation Bio on 5 of the 9 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Allakos' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Generation Bio and Allakos' revenue, earnings per share and valuation.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Allakos, as provided by MarketBeat.com.

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Allakos has a consensus target price of $181.50, indicating a potential upside of 72.86%. Given Allakos' higher probable upside, analysts plainly believe Allakos is more favorable than Generation Bio.

Generation Bio (NASDAQ:GBIO) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Generation Bio and Blueprint Medicines' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Generation Bio and Blueprint Medicines' revenue, earnings per share and valuation.

Generation Bio has higher earnings, but lower revenue than Blueprint Medicines.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Blueprint Medicines, as provided by MarketBeat.com.

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Blueprint Medicines has a consensus target price of $111.00, indicating a potential upside of 17.88%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Generation Bio on 7 of the 10 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Generation Bio and Perrigo, as provided by MarketBeat.com.

Generation Bio presently has a consensus target price of $40.60, indicating a potential upside of 49.26%. Perrigo has a consensus target price of $52.00, indicating a potential upside of 28.30%. Given Generation Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Generation Bio is more favorable than Perrigo.

Valuation & Earnings

This table compares Generation Bio and Perrigo's revenue, earnings per share and valuation.

Perrigo has higher revenue and earnings than Generation Bio.

Profitability

This table compares Generation Bio and Perrigo's net margins, return on equity and return on assets.

Institutional and Insider Ownership

63.3% of Generation Bio shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Perrigo beats Generation Bio on 5 of the 9 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Generation Bio (NASDAQ:GBIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Schrödinger and Generation Bio, as reported by MarketBeat.com.

Schrödinger presently has a consensus price target of $85.50, indicating a potential upside of 15.70%. Generation Bio has a consensus price target of $40.60, indicating a potential upside of 49.26%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than Schrödinger.

Earnings & Valuation

This table compares Schrödinger and Generation Bio's top-line revenue, earnings per share (EPS) and valuation.

Generation Bio has lower revenue, but higher earnings than Schrödinger.

Profitability

This table compares Schrödinger and Generation Bio's net margins, return on equity and return on assets.

Institutional and Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Generation Bio beats Schrödinger on 7 of the 8 factors compared between the two stocks.